Solid Biosciences, which is developing gene therapies to treat Duchenne muscular dystrophy (DMD), filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Cambridge, MA-based company was founded in 2013 plans to list on the Nasdaq under the symbol SLDB. Solid Biosciences filed confidentially on August 4, 2017. J.P. Morgan, Goldman Sachs and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
